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Background: Recent air travel recommendations suggest patients with precapillary pulmonary
hypertension (PCPH) in New York Heart Association (NYHA) functional class 3 and 4 should have
in-flight oxygen without the need for pre-flight testing. However it remains unclear as to how
best to determine patients fitness to fly.
Methods: This study (i) investigates the effect of hypoxic challenge testing (HCT) on the arte-
rial oxygen levels in a cohort of 36 patients with PCPH and (ii) compares the relative frequency
with which FC and HCT predict the requirement for in-flight oxygen.
Results: The degree of arterial hypoxaemia induced by HCT (fall in partial pressure of oxygen
in arterial blood (PaO2) 2.36 kPa, 95% CI 2.06e2.66 kPa) was similar to the drop observed in
other published studies of chronic respiratory diseases.
Following current air travel recommendations based on FC, 25 patients of the cohort would
require in-flight oxygen whilst 10 subjects failed the HCT. Fourteen subjects had flown post-
diagnosis. Of these, nine subjects should have had in-flight oxygen based on FC but were
asymptomatic without. Also one who passed the HCT had developed symptoms during the flight
whilst three who failed the HCT were asymptomatic flying without in-flight oxygen.
Conclusions: Hypoxaemia induced by simulated air travel in patients with PCPH is similar to
that seen in published studies of patients with other chronic respiratory diseases. HCT failed
to predict correctly who had developed symptoms during an aircraft flight in a significant
minority of the study subjects. Similarly guidelines based on functional class result in a majorerial oxygen tension gradient; COPD, chronic obstructive pulmonary disease; CTD-PAH, connective
inspired fraction of oxygen; FC, functional class; HCT, hypoxic challenge testing; mPAP, mean
ew York Heart Association; PaO2, partial pressure of oxygen in arterial blood; PCPH, precapillary
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Hypoxaemia in patients with pulmonary arterial hypertension 299increase in the proportion of patients being advised to use oxygen, many of whom had been
asymptomatic on previous flights without it. More work is required to improve prediction of
need for in-flight oxygen in patients with PCPH.
ª 2012 Published by Elsevier Ltd.Figure 1 Study protocol.Introduction
Recent improvements in medical therapy have meant an
improved quality of life for patients with precapillary
pulmonary hypertension (PCPH) and many of these patients
are now undertaking air travel. However, during a flight
these patients become exposed to hypobaric hypoxia as
aircraft cabins are partly pressurised and travellers may be
exposed to altitudes of up to 2438 m (8000 feet), at which
the partial pressure of oxygen decreases to the equivalent
of breathing an inspired fraction of oxygen (FiO2) of 15% at
sea level. In patients with PCPH this altitude exposure and
concomitant alveolar hypoxia leads not only to arterial
hypoxaemia but also potentially to pulmonary vasocon-
striction, acute right heart strain and theoretically right
heart failure.
Current air travel guidelines recommend that the
requirement for in-flight oxygen in PCPH patients should be
based upon New York Heart Association (NYHA) functional
class (FC) as a surrogate marker for right heart function.
Those in functional class I and II are fit to fly unless the
physician feels that oxygen or an HCT is clinically required
or the patient is hypoxaemic at sea level. Functional class
III and IV patients are recommended to travel with in-flight
oxygen irrespective of baseline saturations. This advice is
expert consensus and is based upon the American Aero-
space Medical Association, the European Respiratory
Society/European Society Cardiology guidelines, the British
Thoracic Society and the UK consensus document on
pulmonary arterial hypertension (PAH).1e5
The problem with producing any recommendations on
in-flight oxygen for patients with PCPH is a paucity of data
regarding the magnitude and time course of the effect of
hypobaric hypoxia on these patients. Many current recom-
mendations on air travel are extrapolated from studies
involving people with common respiratory conditions such
as chronic obstructive pulmonary disease (COPD)6e8 but it is
unclear how best to assess fitness to fly in the context of
pulmonary hypertension.
The aims of this study were twofold. Firstly we wished to
measure the level of hypoxaemia that would develop in
PCPH patients during an aircraft flight simulated by a HCT
and thus determine if it is any more severe than that
reported in other respiratory conditions.9e11 Secondly, we
wanted to compare the relative frequency with current air
travel guidelines using FC to predict the requirement for in-
flight oxygen with previous guidelines using HCT.
Methods
Ethical approval was obtained from the West of Scotland
Research Ethics Service (REC:10/S0709/47) and patients
who participated gave their written informed consent. All
patients were recruited from the Scottish PulmonaryVascular Unit (SPVU). Inclusion required a diagnosis of PAH
or distal chronic thromboembolic pulmonary hypertension
(referred to as PCPH) with saturation of haemoglobin with
oxygen measured by pulse oximetry (SpO2) 90% on air.12
The patients underwent a HCT and the protocol followed
is summarised in Fig. 1. Hypoxaemia was assessed by both
SpO2 and measurement of capillary blood gases (CBG). To
induce alveolar hypoxia, the patient breathed through
a 40% Venturi mask (Intersurgical, UK) driven by 100%
nitrogen (at a flow rate of 10 L min1). The FiO2 induced at
the mouth using this apparatus was measured using an
oxygen sensor (Teledyne analytical instruments, Viamed,
UK) and found to be 15.1%.
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stopped.9 The test was classed as “failed” if PaO2 <6.6 kPa
or SpO2 <85% after 20 min of breathing the air/nitrogen
mixture. Finally, while still breathing the hypoxic gas
mixture, patients were asked to walk 10 m. The rationale
was to mimic the restricted movement patients may have
on an aircraft and observe any changes in SpO2 that
moderate exertion at altitude may have.
A flight history was taken from each study subject. The
questions asked were the date of their last flight, whether
it was made pre-diagnosis or post-diagnosis, their destina-
tion and length of flight, if they experienced any symptoms
(cardio-respiratory, musculoskeletal, neurological) on the
flight and whether they required additional oxygen on the
flight.
Statistical analysis
Data were found to satisfy the ShapiroeWilk test for
normality. Where appropriate, statistical analysis of the
data was performed using paired or unpaired t-tests,
ANOVA with Tukey’s post hoc analysis, ManneWhitney test,
two sample tests of proportion and Fisher’s Exact Test. The
tests were carried out using GraphPad Prism v5 (Graphpad
software, USA) or STATA v12 (Statacorp, USA). A p value
<0.05 was taken to indicate significance.
Results
Thirty six subjects were recruited for the HCT and their
baseline characteristics are shown in Table 1.
The test was well tolerated, with all subjects completing
it without any serious adverse effects. Three patients
reported feeling light-headed and one patient reported
feeling more breathless than usual but these symptoms
were not severe enough to terminate the test. Only one of
these patients went on to fail the test. The mean duration
of the HCTwas 31 min. Partial pressure of oxygen in arterial
blood (PaO2) fell significantly during the test (mean
difference 2.36 kPa, 95% CI 2.06e2.66 kPa) as shown in
Fig. 2(a). At the same time, alveolarearterial oxygen
tension [(Aea)O2] gradient decreased from 4.64 kPa at
baseline to 1.61 kPa at the end of the test (mean difference
3.03 kPa, 95% CI 2.45e3.61 kPa) as shown in Fig. 2(b). There
was no significant change in the SpO2 between the 20 min
point and the 10 m walk, despite increases in heart rate
[Table 2, Fig. 3(a) and (b)].
Twenty-six of the 36 subjects passed the HCT whilst 10
failed. Tables 1 and 2 show the differences between the
group who passed the HCT and the group who failed.
Univariate analysis showed baseline SpO2, PaO2 and AeaO2
gradient to be significantly different between the groups.
However this significance was lost on multivariate analysis.
Importantly functional class was not found as a significant
predictor of those who would fail the HCT and indeed
slightly more subjects in functional class II failed the HCT
than in functional class III (31% vs 27%).
From the flight history data, 39% (n Z 14) had under-
taken air travel after their diagnosis and all these flights
were intercontinental. Only one of these experienced
symptoms during the flight and this subject actually passedthe HCT. A further two subjects had used in-flight oxygen,
with only one of these failing the HCT. Of the 14 who flew
post-diagnosis four failed the HCT, but only one of them
had used in-flight oxygen. Finally, 58% (n Z 21) of the
cohort planned to undergo future air travel.Discussion
A complication of patients with PCPH undertaking air travel
is that they might experience severe hypoxaemia. This
study examined the effect a HCT would have on arterial
oxygen levels and found that 28% of our cohort would fail.
This is no more than observed in studies with other chronic
respiratory diseases, showing up to 40% of COPD patients,
13% of cystic fibrosis patients and 58% of patients with
kyphoscoliosis and/or neuromuscular disease could
fail.10,11,13 When compared with other groups of patients
with respiratory diseases, the fall during the HCT in the
mean PaO2 is no larger. In our cohort the PaO2 fell by
2.36 kPa, compared with 2.6 kPa for cystic fibrosis patients,
3.6 kPa for chest wall disease patients and 2.8 kPa for
patients with COPD.9e11 A possible explanation for this
effect is the decrease observed in (Aea)O2. It has been
shown in both healthy individuals and more recently in
patients with chest wall deformity10,14 that the (Aea)O2
gradient narrows with alveolar hypoxia. This effect could
be due to hypoxic pulmonary vasoconstriction redistribut-
ing perfusion to areas of the lung with better ventilation
and hence lesser degrees of alveolar hypoxia. Recent
evidence has suggested that medication for PAH can worsen
VQ mismatch at rest.15 The data from this study suggest
that the protective mechanism of hypoxic pulmonary
vasoconstriction is sufficiently preserved in patients with
PCPH despite their disease process and medication and
would continue to protect these patients from excessive
hypoxaemia on an aircraft.
In this study hypoxaemia is used as a measure of the
impact of hypobaric hypoxia on the subjects but it may not
be the most appropriate test to determine fitness to fly in
PCPH patients, as it does not assess the effect of the cabin
environment on the right ventricle (RV). Indeed it has been
suggested that the most important issue in a patient with
pulmonary hypertension on an aircraft flight is the risk of RV
failure. However, this appears to be uncommon with very
few actual reported cases16 and there are no published
studies to our knowledge which have specifically looked at
RV function in patients with PCPH while on commercial
aircraft travel. Moreover the actual cabin pressure (and
therefore equivalent sea-level FiO2) experienced by air
travellers can vary and may not be as low as the patients
undergoing the HCT actually experience.17
There are more data looking at the effect of acute
hypoxia on the RV. In healthy volunteers during acute
hypoxia the systolic performance measured by ejection
fraction, stroke volume and end-diastolic volume of the RV
is well maintained despite the increase in pulmonary artery
pressure and afterload.18 One study has looked at the right
and left ventricular contractility in patients with connec-
tive tissue disease-associated PAH (CTD-APAH) exposed to
hypoxia. Patients were exposed to a reduced FiO2 of 14%
and then 10% for a period of 30 min and underwent right
Table 1 Baseline characteristics of study subjects and comparison of those who passed and failed the HCT.
Baseline characteristics All subjects n Z 36 Passed HCT n Z 26 Failed HCT n Z 10 p valuea
Sex, % female 61.1% (22) 61.5% (16) 60% (6) 0.932
Age (years)* 58 [47e66] 57 [45e67] 61 [53e67] 0.61
Diagnosis
IPAH 42% (15) 46% (12) 30% (3)
CTD-APAH 25% (9) 23% (6) 30% (3)
POPAH 6% (2) 8% (2) 0% (0) 0.785
CHD-PAH 3% (1) 4% (1) 0% (0)
CTEPH 25% (9) 19% (5) 40% (4)
mPAP (mmHg) 50.6 [11.5] 50.8 [9.9] 50.3 [15.5] 0.914
CO (L min1) 3.8 [1.2] 3.8 [1.2] 4.1 [1.1] 0.459
PCWP (mmHg) 8.8 [4.9] 8.4 [4.2] 9.8 [6.6] 0.433
NYHA FC*
I 3% (1) 4% (1) 0
II 36% (13) 35% (9) 40% (4) 0.606
III 61% (22) 62% (16) 60% (6)
IV 0 0 0
6MWD (m) 370 [98] 378 [92] 350 [112] 0.449
6MWD SpO2 nadir (%) 90 91 88 0.403
Smoking history (%)
Non-smoker 39%(14) 35% (9) 50% (5)
Ex-smoker 44% (16) 46% (12) 40% (4) 1.0
Current smoker 17% (6) 19% (5) 10% (1)
Medications
PDE5I monotherapy 14 11 3
ETRA monotherapy 7 5 2
Prostanoids monotherapy 0 0 0
Combination therapy 12 7 5
No therapy 3 3 0
FEV1 (% pred) 84.3% [19.2] 84.1% [19.4] 84.9% [19.6] 0.748
FVC (% pred) 98.5% [18.7] 98.5% [19] 98.9% [18.9] 0.659
Actual numbers are shown in brackets (n). All continuous variables are mean [SD] except * which indicates median [interquartile range].
IPAHeidiopathic pulmonary arterial hypertension, CTD-APAHeconnective tissue disease associated pulmonary arterial hypertension,
POPAHeportopulmonary arterial hypertension, CHD-APAHecongenital heart disease associated PAH, CTEPHechronic thromboembolic
pulmonary hypertension, 6MWDe6 minute walk distance, mPAPemean pulmonary arterial pressure, COecardiac output, PCWPepul-
monary capillary wedge pressure, FEV1eforced expiratory volume in 1 s, FVCeforced vital capacity.
a Comparing those who passed and failed the HCT.
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increase observed in the right ventricular end-diastolic and
systolic volume, cardiac index and heart rate, an identical
response to healthy volunteers. Baseline mean pulmonaryFigure 2 (a). Partial pressure of oxygen (PaO2) in arterial blood
shown. (b). The (Aea)O2 gradient is shown before HCT and at the en
indicated by the horizontal lines through the data points.artery pressure (mPAP) was 32 mmHg which showed
a modest increase to 38 mmHg at FiO2 14% and 41.5 mmHg
with a profound hypoxic insult of 10%.19 There were no
reports of problems during the test. A similar response hasbefore HCT and at the end of HCT. Individual patient data are
d of HCT. Individual data points are shown and mean values are
Figure 3 (a) Pulse oximetry oxygen saturation (SpO2) and (b) hear
the 10 m walk. Individual patient data are shown. Mean values are
Table 2 Comparison of measured variables between







SpO2 (%) 95 [2] 93 [2.2] 0.027
PaO2 (kPa) 10.6 [1.2] 9.2 [1.1] 0.002
(Aea)O2 (kPa) 4.3 [1.4] 5.5 [1.2] 0.026
Heart rate (min1) 75 [12] 77 [10] 0.597
Systolic blood
pressure (mmHg)
119 [19] 108 [15] 0.110
Diastolic blood
pressure (mmHg)
80 [14] 74 [16] 0.296
Respiratory rate
(min1)
18 [6] 16 [3] 0.4
Borg score* 0 [0e0.6] 0.5 [0e1] 0.42
End of HCT
SpO2 (%) 89 [3] 83 [1] <0.0001
PaO2 (kPa) 8.2 [0.7] 6.6 [0.5] <0.0001
(Aea)O2 (kPa) 1.4 [0.9] 2.3 [1.1] 0.008
Heart rate (min1) 74 [13] 80 [10] 0.456
Systolic blood
pressure (mmHg)
116 [20] 106 [13] 0.164
Diastolic blood
pressure (mmHg)
77 [14] 73 [17] 0.442
Respiratory rate
(min1)
18 [6] 16 [4] 0.256
Borg score* 0.3 [0e1] 0.5 [0e1] 0.67
10 m walk
SpO2 (%) 89 [3] 83 [2] <0.0001
Heart rate (min1) 88 [10] 99 [9] 0.01
Respiratory rate
(min1)
20 [7] 19 [4] 0.73
Borg score* 0.5 [0e2] 1 [0e2] 0.62
Actual numbers are shown in brackets (n). All continuous vari-
ables are mean [SD] except * which indicates median [inter-
quartile range].
SpO2epulse oximetry oxygen saturation, PaO2epartial pressure
of oxygen in arterial blood, PaCO2epartial pressure of carbon
dioxide in arterial blood, (Aea)O2ealveolarearterial oxygen
gradient.
302 R.M. Burns et al.been seen in patients with COPD some of whom had
pulmonary hypertension.20e22 It would appear that even
with severe alveolar hypoxia (FiO2 10%) the effect on
pulmonary haemodynamics may be modest and unlikely to
affect the RV adversely for the short period required for an
aircraft flight and indeed maximal hypoxic vasoconstriction
is achieved by 2 h.23 However one study showed that 2
children out of a cohort of 22 with congenital heart disease
and pulmonary hypertension, developed a large increase in
pulmonary vascular resistance (PVR) when exposed to
hypoxia (although others actually decreased their PVR).24
The extent by which this effect is relevant to adults with
non-congenital heart disease associated PAH is unclear.
An alternative way to stress the RV which results in
equivalent rises in mPAP and hence RV afterload is exercise.
It has been shown using ambulatory pulmonary artery
catheters that during exercise mean increases in mPAP of
9.6 mmHg can be seen, with some patients increasing by as
much as 19 mmHg.25 Most of these subjects manage such
effort without adverse effect. What is more, we actively
encourage our patients to undertake exercise regularly
despite being aware of these acute effects on RV afterload.
In addition it has been demonstrated in patients with
coexistent COPD and pulmonary hypertension that during
eight hour periods of sleep the mPAP can rise to levels seen
during exercise.26 Clearly during sleep the RV copes in
general with these increases in the mPAP and many flights
are shorter than eight hours.
From our flight history questionnaire, 10 of the people
who have been on a flight since their diagnosis would be
advised to use supplementary oxygen based on current
recommendations, although only 4 actually failed the HCT.
Moreover only 1 of these patients had actually used in-flight
oxygen. None of these patients experienced symptoms
during the flight. This agrees with previous studies which
have shown that despite being hypoxaemic during aircraft
flight very few actually experienced any symptoms or
needed unscheduled respiratory healthcare.27 In addition
some patients had symptoms during the HCT and still
passed suggesting that some patients may experience
symptoms above the threshold for failing a HCT. Therefore
both HCT and FC assessment are not perfect at identifying
patients who may have symptoms during aircraft travel.t rate are shown before, during, at the end of the HCT and after
indicated as horizontal line through data points.
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and numbers increasing, more people with chronic health
problems such as PCPH will want to fly.28The consequences
of the current recommendations and their implications for
air travel in these patients should not be underestimated as
it could limit their potential to travel by air and impair their
quality of life. There is great disparity in the attitudes of
airlines to the provision of in-flight oxygen, demonstrated
by a recent report by the UK Pulmonary Hypertension
Association.29 Some airlines do not allow additional in-flight
oxygen, some can charge in excess of £200 for a round trip,
while others require the purchase of an additional seat if
oxygen is required.29 Perhaps one of the principal aims of
air travel guidelines should be to minimise the proportion of
patients to whom we recommend in-flight oxygen without
jeopardising their safety. Whilst failing a HCT is not a defi-
nite predictor of acute RV failure and subsequent problems
during air travel, it does indicate the likelihood of devel-
oping significant arterial hypoxaemia during a flight. Using
recommendations based on functional class may both
increase the proportion of patients who must now be
advised to arrange oxygen for their flight whilst at the same
time is not proven to improve the accuracy of predicting
problems should oxygen not be provided. In addition in this
study functional class did not predict whether a subject
would fail the HCT (31% with FC II vs 27% FC III) and so was
a poor indicator of the potential development of severe
arterial hypoxaemia. This study is not suggesting that use of
HCT is better than using FC to determine need for in-flight
oxygen but merely aiming to compare and contrast two
different approaches to assessing the in-flight oxygen
requirement. The HCT is an imperfect test for assessing this
as it measures arterial hypoxaemia whereas in patients with
PAH the ideal end-point would be the effect on RV function.
In addition the need for in-flight oxygen for a patient who
actually fails a HCT has not been proven conclusively in
clinical trials but is based on expert consensus. There are
further cost implications if all patients with PAH were to
undergo a HCT, with no data available to suggest that this
would be a cost effective strategy.
To our knowledge this is the largest study of patients with
PCPH undergoing a hypoxic challenge test. Patients with
baseline SpO2 >95% and <92% were included, allowing
conclusions to be drawn on patients not always tested. A
further strength was the addition of a 10 m walk, which is
not routinely performed during a HCT, to mimic mild exer-
cise on an aircraft. This study has a number of limitations.
The current most accepted standard to test for in-flight
oxygen requirement and potential issues arising during
a flight would be to use a hypobaric chamber. For practical
purposes a hypoxic challenge test was used assuming that
normobaric hypoxia experienced by the patient equated to
the hypobaric hypoxia of altitude. There is no physiological
rationale to think that this would be otherwise.30 Further-
more the Venturi modification HCT has been validated as an
equally effective test against the standard of measuring
oxygenation in a hypobaric chamber.31 The duration of the
test is not as long as even a short haul flight would be.
However studies have shown that after 20 min there is
equilibration of the hypoxic gas mixture.
In conclusion, patients with precapillary pulmonary
hypertension have similar degrees of hypoxaemia duringthe HCT to patients with other respiratory diseases. Current
guidelines based on functional class result in a major
increase in the number of patients being advised to use
oxygen in-flight compared with older guidelines based on
HCT. Both approaches recommend oxygen in patients who
were asymptomatic on flights undertaken post-diagnosis
but before this study. HCT did not identify one patient who
developed symptoms during a flight. Further work is
required to identify more accurate predictors for deter-
mining the need for in-flight oxygen in patients with PCPH.
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